Inventor
MARK IAN KEMP
Inventor
GB
Overview
Patents· 9 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations38%
C07DHeterocyclic compounds38%
A61KPreparations for medical, dental or toiletry purposes17%
C07CAcyclic or carbocyclic compounds4%
Y02ATechnologies for adaptation to climate change4%
PatentTitleYear
11,993,595Compounds202411,958,833Compounds202411,945,7971-cyano-pyrrolidine derivatives as dub inhibitors202411,472,798Compounds202211,414,402Sulfonamide-substituted cyanopyrrolidines with activity as DUB inhibitors202211,370,784Cyano-substituted heterocycles with activity as inhibitors of USP30202211,352,3391-cyano-pyrrolidine derivatives as DUB inhibitors202211,306,0964,6 dihydropyrrolo [3,4-C] pyrazole-5 (1H)-carbonitrile derivates for treating cancer202211,236,092Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2024Patents assigned to MISSION THERAPEUTICS LTD (9)· patent assignee history
2022–2024Based in GB· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| MISSION THERAPEUTICS LTD | 9 | 2022–2024 |
Locations
| Location | Patents | Span |
|---|---|---|
| GB | 9 | 2022–2024 |